Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells

Journal of Natural Medicines

Volumn 66, Issue 1, 2012, Pages 8-16

  Lee, Ji Won ^a   Iwahashi, Ayumi ^a   Hasegawa, Shin Ichi ^a   Yonezawa, Takayuki ^a   Jeon, Won Bae ^b   Cha, Byung Yoon ^a   Nagai, Kazuo ^a   Woo, Je Tae ^a  

^a CHUBU UNIVERSITY   (Japan)

^b Daegu Gyeongbuk Institute of Science and Technology   (South Korea)

Author keywords

Coptisine; NFATc1; Osteoclast; RANKL

Indexed keywords

CALCITRIOL; COPTISINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL ACTIVITY; CELL MATURATION; CELL SURVIVAL; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COPTIS; DRUG MECHANISM; DRUG STRUCTURE; GENE; GENE EXPRESSION REGULATION; IN VITRO STUDY; MACROPHAGE; MALE; METABOLIC INHIBITION; MITOSIS INHIBITION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOPROTEGERIN GENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANKL GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; BERBERINE; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; CALCITRIOL; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MALE; MICE; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; PHOSPHORYLATION; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84856225965     PISSN: 13403443     EISSN: 18610293     Source Type: Journal    
DOI: 10.1007/s11418-011-0537-7     Document Type: Article

References (30)

1. Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251-264 (Pubitemid 46054562)
2. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor jB (RANK) receptors. J Exp Med 190:1741-1754 (Pubitemid 30013841)
3. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342 (Pubitemid 40852708)
4. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12 (Pubitemid 30026926)
5. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T (2000) Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141: 3478-3484 (Pubitemid 32269038)
6. Takahashi N, Udagawa N, Kobayashi Y, Suda T (2007) Generation of osteoclasts in vitro, and assay of osteoclast activity. Methods Mol Med 135:285-301
7. Teitelbaum SL (2004) RANKing c-Jun in osteoclast development. J Clin Invest 114:463-465 (Pubitemid 39572093)
8. Phillipson JD, Anderson LA (1989) Ethnopharmacology and Western medicine. J Ethnopharmacol 25:61-72 (Pubitemid 19073013)
9. Li H, Miyahara T, Tezuka Y, Namba T, Nemoto N, Tonami S, Seto H, Tada T, Kadota S (1998) The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan. Biol Pharm Bull 21:1322-1326 (Pubitemid 29021794)
10. Sun J, Ma JS, Jin J, Wang HS, Wen QH, Zhang HG, Zhou QL (2006) Qualitative and quantitative determination of the main components of huanglianjiedu decoction by HPLC-UV/MS. Yao Xue Xue Bao 41:380-384 (Pubitemid 43844777)
11. Tang LQ, Wei W, Chen LM, Liu S (2006) Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 108:109-115 (Pubitemid 44498992)
12. Kuo CL, Chi CW, Liu TY (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137
13. Yokozawa T, Satoh A, Cho EJ, Kashiwada Y, Ikeshiro Y (2005) Protective role of Coptidis Rhizoma alkaloids against peroxynitrite- induced damage to renal tubular epithelial cells. J Pharm Pharmacol 57:367-374 (Pubitemid 40314436)
14. Tan B, Ma Y, Shi R, Wang T (2007) Simultaneous quantification of three alkaloids of Coptidis Rhizoma in rat urine by high-performance liquid chromatography: application to pharmacokinetic study. Biopharm Drug Dispos 28:511-516 (Pubitemid 351200989)
15. Li HL, Zhang WD, Liu RH, Zhang C, Han T, Wang XW, Wang XL, Zhu JB, Chen CL (2006) Simultaneous determination of four active alkaloids from a traditional Chinese medicine Corydalis saxicola Bunting. (Yanhuanglian) in plasma and urine samples by LC-MS-MS. J Chromatogr B Analyt Technol Biomed Life Sci 831:140-146 (Pubitemid 43155788)
16. Qin L, Han T, Zhang Q, Cao D, Nian H, Rahman K, Zheng H (2008) Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. J Ethnopharmacol 23:271-279
17. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357 (Pubitemid 30649812)
18. Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7:292-304 (Pubitemid 46480961)
19. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y (2006) Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 24:33-63
20. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U (1997) Requirement for NF-jB in osteoclast and B-cell development. Genes Dev 11:3482-3496 (Pubitemid 28023969)
21. Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-jB1 and NF-jB2. Nat Med 3:1285-1289 (Pubitemid 27508833)
22. Hu JP, Nishishita K, Sakai E, Yoshida H, Kato Y, Tsukuba T, Okamoto K (2008) Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-jB and Akt pathways. Eur J Pharmacol 580:70-79
23. Chang EJ, Kim HJ, Ha J, Kim HJ, Ryu J, Park KH, Kim UH, Lee ZH, Kim HM, Fisher DE, Kim HH (2007) Hyaluronan inhibits osteoclast differentiation via Toll-like receptor 4. J Cell Sci 120:166-176 (Pubitemid 46206659)
24. Chambers TJ, Magnus CJ (1982) Calcitonin alters behaviour of isolated osteoclasts. J Pathol 136:27-39 (Pubitemid 12213616)
25. Väänänen HK, Zhao H, Mulari M, Halleen JM (2000) The cell biology of osteoclast function. J Cell Sci 113:377-381 (Pubitemid 30116644)
26. Destaing O, Saltel F, Géminard JC, Jurdic P, Bard F (2003) Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein. Mol Biol Cell 14:407-416 (Pubitemid 36237005)
27. Saltel F, Destaing O, Bard F, Eichert D, Jurdic P (2004) Apatitemediated actin dynamics in resorbing osteoclasts. Mol Biol Cell 15:5231-5241 (Pubitemid 39564720)
28. Lakkakorpi PT, Väänänen HK (1990) Calcitonin, prostaglandin E2, and dibutyryl cyclic adenosine 30,50-monophosphate disperse the specific microfilament structure in resorbing osteoclasts. J Histochem Cytochem 38:1487-1493 (Pubitemid 20311140)
29. Nakamura I, Takahashi N, Sasaki T, Tanaka S, Udagawa N, Murakami H, Kimura K, Kabuyama Y, Kurokawa T, Suda T, Yasuhisa F (1995) Wortmannin, a specific inhibitor of phosphatidylinositol- 3 kinase, blocks osteoclastic bone resorption. FEBS Lett 361:79-84
30. Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y, Hori M, Suda T (1996) Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology 137:4685-4690 (Pubitemid 26403306)